Documentos de Académico
Documentos de Profesional
Documentos de Cultura
(/lang/en)
A
Abbssttrraacctt
O
Obbjjeeccttiivvee:: Previous studies in patients with Graves disease (GD) and Graves
ophtalmopathy (GO) have focused mainly on the levels of TSH-receptor antibodies
(TRAb). Our aim was to investigate the levels of TRAb, thyroid peroxidase (TPOAb) and
thyroglobulin antibodies (TGAb) in patients with GD with and without GO.
M
Maatteerriiaallss aanndd M
Meetthhooddss:: 98 patients with GD were included in this retrospective
study-76 women and 22 men. Thirty-nine patients had manifested GO - 28 women, 11
men. The serum levels of thyroid stimulating hormone (TSH) and free thyroxine (fT4)
were measured by a chemiluminescence assay; TPOAb and TGAb - by an
electrochemiluminescence method, and TRAb - by an enzymatic-substrate method-
ELISA.
R
Reessuullttss:: Median serum levels of TSH and fT4 were 0.079 IU/l and 37.7 pmol/l in
patients with GD + GO versus 0.420 IU/l and 23.2 pmol/l in patients with GD without
GO (p=0.04 for TSH and p=0.02 for fT4). In GD + GO, we found higher levels of TRAb
(22.1 versus 10.4 IU/L, p<0.001) and TGAb (412.5 vs. 190.6 IU/l, p<0.001), and
lower levels of TPOAb (390.6 vs. 690.4 IU/l, p=0.001) than in GD alone.
C
Coonncclluussiioonn:: Higher levels of TGAb and TRAb, and lower levels of TPOAb are found in
patients with GD with GO compared to patients without ophtalmopathy. These findings
might open new perspectives in studying the pathogenesis of GO. Turk Jem 2010; 14:
50 3
K
Keeyy w
woorrddss:: Graves disease, graves ophtalmopathy, thyroid antibodies
Ö
Özzeett
A
Ammaaçç:: Graves hastalığı (GH) ve Graves oftalmopati (GO) hastaları üzerinde daha önce
yapılmış olan çalışmalar, genel olarak TSH-reseptör antikoru (TRAb) düzeylerine
odaklanmıştır. Bu çalışmanın amacı GH ve GO hastalarının TRAb, tiroid peroksidaz
(TPOAb) ve tiroglobulin (TGAb) düzeylerini araştırmaktır.
G
Geerreeçç vvee YYöönntteem
mlleerr:: GH tanısıyla izlenen 98 hasta, (76 kadın, 22 erkek) bu
resrospektif çalışmaya dahil edildi. 39 hastada (28 kadın, 11 erkek) GO görüldü. Tiroid
stimulan hormon (TSH) ve serbest tiroksin (FT4) düzeyleri kemiluminesan yöntemi,
TPOAb ve TGAb düzeyleri elektrokemiluminesan yöntemi ile, TRAb düzeyi ise enzim-
substrat metodu-ELISA ile ölçüldü.
B
Buullgguullaarr:: GH+GO hastalarında medyan serum TSH ve FT4 düzeyleri sırasıyla 0.079
IU/I ve 37,7 pmol/I iken GO bulunmayan GH hastalarında TSH ve FT4 düzeylerinin
sırasıyla 0,420IU/I ve 23,2 pmol/I olduğu görülmüştür (TSH için p=0,04, FT4 için
p=0,02). GH+GO hastalarının TRAb ve TGAb düzeyleri yalnızca GH mevcut hastalara
göre daha yüksek iken (sırasıyla 22,1 e karşın 10,4IU/L, p<0,001 ve 412,5 e karşın
190.6IU/I, p<0,001), TPOAb düzeyleri daha düşüktü (390,6 ya karşın 690,4IU/I,
p=0,001).
SSoonnuuçç:: GO nun eşlik ettiği GH hastaları oftalmopati bulunmayan GH hastaları ile
kıyaslandığında, TGAb ve TRAb düzeylerinin daha yüksek, TPOAb düzeyinin daha
düşük olduğu görüldü. Bu bulgular GO patogenezi üzerinde yapılacak çalışmalar için
yeni perspektifler sunabilir. Türk Jem 2010; 14: 50-3
A
Annaahhttaarr kkeelliim
meelleerr:: Graves hastalığı, graves of talmopati, tiroid otoantikore
IInnttrroodduuccttiioonn
M
Maatteerriiaallss aanndd M
Meetthhooddss
PPaattiieennttss
This is a cross-sectional retrospective study, which includes 98 patients with GD
treated at the Endocrinology clinic of the Alexandrovska Hospital between 2002 and
2008. Seventy-six patients were female (mean age: 49.7±10.6 years) and twenty-two
were male (mean age: 42.7±11.6 years). They had been referred for hospitalization
mainly because of fluctuations in their thyroid function during antithyroid drug
therapy or development of GO. The mean duration of GD was 1.6 ± 0.8 years. 46
patients had newly discovered hyperthyroidism. At the time of referral, the remaining
52 patients were taking antithyroid drugs. None of them had been treated previously
with corticosteroids, radio-iodine or surgery. All procedures described below are part
of the routine work-up of GD patients at our Endocrinology clinic and were in
accordance with the ethical standards of the Committee on human experimentation at
the Alexandrovska Hospital as well as on a national level. All patients gave their
informed consent for data processing prior to their hospitalization.
M
Meetthhooddss
The medical history included family history of thyroid disorders, smoking habits,
symptoms of thyroid dysfunction as well as current treatment. A physical examination
and anthropometric measurements were then performed. The palpation of the thyroid
gland was followed by thyroid ultrasound on a Fukuda-Denshi 5.500 device (Fukuda
Corp., Tokyo, Japan). The thyroid volume was calculated according to J. Brunn et al. in
milliliters (13). Thyroid hormones-thyroid stimulating hormone (TSH) and free
thyroxine (fT4) were measured by a chemiluminescence method (Bayer
Diagnostics,Leverkusen, Germany). Anti-peroxidase (TPOAb) and TGAb were
measured by an electrochemiluminescence method (Hoffmann-La Roche Ltd., Basel,
Switzerland). TRAb were measured by an enzymatic-substrate method-ELISA (DRG
International Inc., Mountainside, NJ, USA) and represented thyroid-binding inhibitory
immunoglobulins. The upper normal limits for thyroid antibody titers were set as
follows: TPOAb < 34 IU/l, TGAb < 115 IU/l and TRAb < 1.5 IU/l.
The diagnosis of GO was based mainly on the clinical picture (eyelid retraction,
periorbital swelling, diplopia and others) according to the American Academy of
Ophthalmology diagnostic criteria. The grade of the eye disease was estimated
according to the NOSPECS classification (1) and the clinical activity score (CAS)
according to Mourits et al. (14). All patients were referred for precise work-up by an
experienced ophthalmologist at our University Hospital. Grade of exophthalmos,
intraocular pressure, ocular motility and visual acuity were recorded.
The statistical analysis was performed on a SPSS 13.0 for Windows package (SPSS
Inc., Chicago, IL, USA). Descriptive statistics, two-sided Students t-test, the Mann-
Whitney U test, non-parametric Kruskal-Wallis and parametric ANOVA, and Spearmans
correlation analysis were performed. Significance was set as p≤0.05.
R
Reessuullttss
Thirty-nine study participants had manifested GO-28 women and 11 men. Therefore,
the prevalence of GO in our sample of ninety-eight patients with GD was 36.8% in
women and 50% in men. According to the NOSPECS classification, three patients
(7.7%) had grade 1 GO, seven patients (17.9%) had grade 2, eleven patients
(28.2%)-grade 3, fifteen patients (38.4%)-grade 4, two patients (5.1%)-grade 5 and
one (2.6%)-grade 6. Twenty-five patients with GO had a CAS score above 4 (an active
disease) and the mean CAS score for the GO group as a whole was 4.8±1.2.
The clinical data of the participants including the thyroid volume measured by
ultrasound are summarized in Table 1. (Javascript:ResimGoster('sayilar/67/1-1.jpg'))
Smoking was more common in patients with GD + GO than in those without GO. The
odds ratio for current smoking in the presence of GO was 1.44. Thyroid volume did not
show significant differences between the GO+and the GO-subgroups.
The hormonal and thyroid autoantibody levels of the participants are displayed in
Table 2. (Javascript:ResimGoster('sayilar/67/1-2.jpg')) Fifty-six of all ninety-eight
participants (57.1%) were hyperthyroid (low TSH, elevated fT4) at the time of
evaluation (48 newly discovered and eight under antithyroid treatment). Another
twelve of the fifty treated patients had low TSH despite normal fT4 levels (24%). Five
of the fifty treated patients had low normal fT4 levels and TSH<10 IU/l (iatrogenic
subclinical hypothyroidism in 10%).
The patients with GO were more hyperthyroid than those without GO. The levels of all
three thyroidal antibodies showed significant differences in the subgroups with and
without GO. The presence of GO was associated with higher levels of TRAb and TGAb
and lower levels of TPOAb. There was no relevant correlation between the CAS and the
levels of TRAb and TGAb (Spearman's r=0.2, p=0.03) or of TPOAb ( Spearman's
r=0.15, p=0.04). The correlations of thyroid autoantibody levels with the grade of GO
were not significant.
D
Diissccuussssiioonn
C
Coonncclluussiioonn
In summary, we performed a pilot study in patients with GD with and without GO and
found different levels of TRAb, TGAb and TPOAb in case of presence or absence of GO.
Our study should be regarded as an urge for conducting further large prospective
studies relating thyroid autoimmunity with the clinical course of GO in GD and for
further elucidation of the pathogenesis of GO.
A
Acckknnoow
wlleeddggm
meennttss
The authors wish to thank Assoc. Prof. V. Christov, former Head of the Endocrinology
Clinic, for his encouragement in this work and Dr. L. Wezenkova and Dr. D. Manolov for
their help in collecting the patients data.
A
Addddrreessss ffoorr C
Coorrrreessppoonnddeennccee:: Mihail A. Boyanov MD, DMSci Endocrinology Clinic,
Alexandrovska Hospital 1, G. Sofiiski Str., Sofia 1431 Bulgaria Phone: + 3592 9230
784 E-mail: mihailboyanov@yahoo.com (mailto:mihailboyanov@yahoo.com)
Recevied: 28.11.2010 Accepted: 07.12.2010
R
Reeffeerreenncceess
1. Perros P, Dickinson AJ. Ophtalmopathy. Werner and Ingbar's The Thyroid: Braverman LE, Utiger RD, eds. A
Fundamental and Clinical Text. Philadelphia; Lippincott Williams and Wilkins; 2005:474-87.
2. Lehmann GM, Feldon SE, Smith TJ, Phipps RP. Immune mechanisms in thyroid eye disease. Thyroid
2008;18:959-65.
3. Mizokami T, Salvi M, Wall JR. Eye muscle antibodies in Graves ophthalmopathy: pathogenic or secondary
4. Ando T, Latif R, Davies TF. Thyrotropin receptor antibodies: new insights into their actions and clinical
5. Bahn RS. Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-
6. Anja KE, Marco P, Hildegard L, Markus N, Klaus M, Sebastian L, Christian H, Joachim E, Nils G. Morgenthaler
Thyrotropin receptor autoantibodies are independent risk factors for Graves ophthalmopathy and help to predict
7. Gerding, MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, 8. Prummel MF. Association of
thyrotrophin receptor antibodies with the clinical features of Graves ophthalmopathy. Clin Endocrinol
2000;52:267-71.
8. Geen J, Howells RC, Ludgate M, Hullin DA, Hogg SI. The prevalence of anti-acetylcholinesterase antibodies in
9. Kuroki T, Ruf J, Whelan L, Miller A, Wall JR. Antithyroglobulin monoclonal and autoantibodies cross-react with
an orbital connective tissue membrane antigen: a possible mechanism for the association of ophthalmopathy
tissues from patients with thyroid-associated ophthalmopathy: predominant localization in fibroadipose tissue.
Thyroid 2002;12:351-60.
11. Marinò M, Lisi S, Pinchera A, Mazzi B, Latrofa F, Sellari-Franceschini S, McCluskey RT, Chiovato L.
2001;11:177-85.
12. Wright-Pascoe R, Smikle MF, Barton EN, James OB. Limited usefulness of antithyroperoxidase and
13. Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC. Volumetrie der Schilddrüse mittels Real-time-
14. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of
15. Eckstein AK, Lösch C, Glowacka D, Schott M, Mann K, Esser J, Morgenthaler NG. Euthyroid and primarily
hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J
Ophthalmol 2009;93:1052-6.
16. Eckstein A, Mann K, Kahaly GJ, Grussendorf M, Reiners C, Feldkamp J, Quadbeck B, Bockisch A, Schott M.
Role of TSH receptor autoantibodies for the diagnosis of Graves disease and for the prediction of the course of
hyperthyroidism and ophthalmopathy. Recommendations of the Thyroid Section of the German Society of
17. Goh SY, Ho SC, Seah LL, Fong KS, Khoo DH. Thyroid autoantibody profiles in ophthalmic dominant and
thyroid dominant Graves disease differ and suggest ophthalmopathy is a multiantigenic disease. Clin Endocrinol
Oxf 2004;60:600-7.
18. Hsu SY, Chang CH, Su MY, Wang HZ, Tsai RK. Correlation between clinical activity score and thyroid
19. Khoo DH, Ho SC, Seah LL, Fong KS, Tai ES, Chee SP, Eng PH, Aw SE, Fok AC. The combination of absent
thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves disease identifies a
20. Acuna OM, Athannassaki I, Paysse EA. Association between thyroid-stimulating immunoglobulin levels and
ocular findings in pediatric patients with Graves disease. Trans Am Ophthalmol Soc 2007;105:146-50.
21. MyÊliwiec J, Kretowski A, Stepie A, Miroczuk K, Kinalska I. Thyrotropin receptor antibodies detected by the
human recombinant TBII assay-a surrogate marker for autoimmune activity in Graves ophthalmopathy? Med Sci
Monit 2002;8:59-62.
22. Bromberg N, Werner RS, Sgarbi JA, Werner MC, Romaldini JH. The evolution of the ophthalmopathy during
antithyroid drug therapy and its relationship with serum thyroglobulin and antithyroglobulin antibody in patients
23. Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J, Morgenthaler NG. Clinical
results of anti-inflammatory therapy in Graves ophthalmopathy and association with thyroidal autoantibodies.
Clin Endocrinol Oxf 2004;61:612-8.
24. Kubota S, Ohye H, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Kuma K, Miyauchi A. Effect of high dose
methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH
25. Lozanov B, Kirilov G, Ivanova R, Khubaveshki S. The effect of thyrostatic treatment on circulating thyrotropin-
26. Kim WB, Chung HK, Park YJ, Park DJ, Tahara K, Kohn LD, Cho BY. The prevalence and clinical significance of
blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves disease. Thyroid 2000;10:579-86.
27. Kim WB, Chung HK, Park YJ, Park DJ, Lee HK, Cho BY. Clinical significance of classification of Graves disease
according to the characteristics of TSH receptor antibodies. Korean J Intern Med 2001;16:187-200.
Copyright © 2018
Bu sitenin tüm hakları Turkish Journal of Endocrinology and Metabolism'ne aittir.